XML 29 R5.htm IDEA: XBRL DOCUMENT v3.24.0.1Close
Consolidated Balance Sheets - USD ($)
$ in Millions
Dec. 31, 2023
Dec. 31, 2022
 [1]
Assets    
Cash and cash equivalents $ 7,822 $ 5,924
Investments 925 905
Accounts receivable, net 17,722 17,218
Inventories 5,645 4,777
Other current assets 2,169 1,298
Assets of businesses held for sale 3,068 0
Total current assets 37,351 30,122
Long-term investments 17,985 16,288
Reinsurance recoverables 4,835 5,416
Property and equipment 3,695 3,774
Goodwill 44,259 45,811
Other intangible assets 30,863 32,492
Other assets 3,421 2,704
Separate account assets 7,430 7,278
Assets of businesses held for sale, non-current 2,922 0
TOTAL ASSETS 152,761 143,885 Close
Liabilities    
Current insurance and contractholder liabilities 5,514 5,409
Pharmacy and other service costs payable 19,815 17,070
Accounts payable 8,553 7,775
Accrued expenses and other liabilities 9,955 7,978
Short-term debt 2,775 2,993
Liabilities of businesses held for sale 2,104 0
Total current liabilities 48,716 41,225
Non-current insurance and contractholder liabilities 10,904 11,976
Deferred tax liabilities, net 7,173 7,786
Other non-current liabilities 3,441 2,766
Long-term debt 28,155 28,100
Separate account liabilities 7,430 7,278
Liabilities of businesses held for sale, non-current 591 0
TOTAL LIABILITIES 106,410 99,131 Close
Contingencies — Note 24
Redeemable noncontrolling interests 107 66 Close
Shareholders' equity    
Common stock [2] 4 4
Additional paid-in capital 30,669 30,233
Accumulated other comprehensive loss (1,864) (1,658)
Retained earnings 41,652 37,940
Less: Treasury stock, at cost (24,238) (21,844)
TOTAL SHAREHOLDERS' EQUITY 46,223 44,675
Other noncontrolling interests 21 13
Total equity 46,244 44,688 Close
Total liabilities and equity $ 152,761 $ 143,885
[1] Amounts have been restated to reflect the adoption of Targeted Improvements to the Accounting for Long-Duration Contracts in 2023. See Note 2 to the Consolidated Financial Statements for further information.
[2] Par value per share, $0.01; shares issued, 400 million as of December 31, 2023 and 398 million as of December 31, 2022; authorized shares, 600 million.